CD44 predicts early recurrence in pancreatic cancer patients undergoing radical surgery

  • Chih Po Hsu
  • , Li Yu Lee
  • , Jun Te Hsu*
  • , Yu Pao Hsu
  • , Yu Tung Wu
  • , Shang Yu Wang
  • , Chun Nan Yeh
  • , Tse Ching Chen
  • , Tsann Long Hwang
  • *Corresponding author for this work

Research output: Contribution to journalJournal Article peer-review

19 Scopus citations

Abstract

Background/Aim: Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive types of digestive cancer. Recurrence within one year after surgery is inevitable in most PDAC patients. Recently, cluster of differentiation 44 (CD44) has been shown to be associated with tumor initiation, metastasis and prognosis. This study aimed to explore the correlation of CD44 expression with clinicopathological factors and the role of CD44 in predicting early recurrence (ER) in PDAC patients after radical surgery. Materials and Methods: PDAC patients who underwent radical resection between January 1999 and March 2015 were enrolled in this study. Tumor recurrence within 6 months after surgery was defined as ER. Immunohistochemical staining was performed with anti-CD44 antibodies. The association between clinico - pathological parameters and CD44 expression was analyzed. Predictors for ER were also assessed with univariate and multivariate analyses. Results: Overall, 155 patients were included in this study. Univariate analysis revealed CA19-9 levels (p=0.014), CD44 histoscores (H-scores; p=0.002), differentiation (p=0.010), nodal status (p=0.005), stage (p=0.003), vascular invasion (p=0.007), lymphatic invasion (p<0.001) and perineural invasion (p=0.042) as risk factors for ER. In multivariate analysis, high CA19-9 levels and CD44 H-scores and poor differentiation independently predicted ER. Conclusion: High CA19-9 levels, CD44 Hscores and poor differentiation are independent predictors for ER in PDAC patients undergoing radical resection. Therefore, the determination of CD44 expression might help in identifying patients at a high risk of ER for more aggressive treatment after radical surgery.

Original languageEnglish
Pages (from-to)1533-1540
Number of pages8
JournalIn Vivo
Volume32
Issue number6
DOIs
StatePublished - 01 11 2018

Bibliographical note

Publisher Copyright:
© 2018 Institute of Electrical and Electronics Engineers Inc. All rights reserved.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • CD44
  • Early recurrence
  • Pancreatic cancer
  • Surgery

Fingerprint

Dive into the research topics of 'CD44 predicts early recurrence in pancreatic cancer patients undergoing radical surgery'. Together they form a unique fingerprint.

Cite this